TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

Summary

Primary Objective • To evaluate the pharmacodynamic effects on metabolic endpoints (malonyl carnitine and tripalmitin levels) following short-term treatment with TVB-2640 in patients with resectable cancers Secondary Objectives * To determine if short-term treatment with TVB-2640 decreases cancer cell proliferation. * To examine other biological endpoints and determine if TVB-2640 inhibits cell survival signaling and lipid biogenesis. * To perform comprehensive metabolomic analysis in tumor tissues to identify metabolic alterations induced by TVB-2640 treatment. * To correlate FASN levels in tumor with metabolic and biological endpoints to determine if FASN inhibition has more pronounced effects in patients with increased expression.

Timeline

Start

2017-10-06

Primary completion

2023-10-22

Completion

2023-10-22

Drugs

Indications